(38 days)
The Sensititre® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Haemophilus influenzae; Streptococcus pneumoniae and Streptococcus species. This 510(k) is for the addition of Streptococcus spps. to Gemifloxacin (0.03 -0.5 ug/mL), Linezolid (0.5-4 ug/mL), Levolloxacin (0.5-16 ug/mL) for use with the Sensitite® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility Plates.
Not Found
The provided document is a 510(k) premarket notification letter from the FDA regarding a Sensititre® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC susceptibility plate. This device is an in vitro diagnostic product for clinical susceptibility testing of specific bacterial strains against antimicrobial agents.
Therefore, the requested information about acceptance criteria for a medical imaging AI device or an AI model, ground truth, expert consensus, and MRMC studies is not applicable to this document.
The document discusses the regulatory approval of a microbiology testing plate based on substantial equivalence to legally marketed predicate devices, not on performance criteria that would involve AI or human reader studies.
Here's why the requested information cannot be extracted from the provided text:
- This is not an AI device. The device is a microbiology susceptibility plate, a lab consumable for determining how effective an antibiotic is against a specific bacterium. It's a chemical/biological assay, not an AI or imaging device.
- No AI performance metrics are discussed. The document deals with regulatory matters for an in vitro diagnostic product. It doesn't mention sensitivity, specificity, AUC, or any other performance metrics typically associated with AI.
- No human reader studies are mentioned. There's no indication of radiologists, experts, or their performance with or without AI assistance.
- No ground truth establishment for AI is present. The "ground truth" for a microbiology susceptibility plate would typically be the minimum inhibitory concentration (MIC) determined by a reference method, which is a standardized laboratory procedure, not expert consensus or pathology in the context of AI.
- Training or test set sample sizes for an AI algorithm are not relevant.
In summary, the provided text does not contain any of the information requested for AI device acceptance criteria or studies.
{0}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The caduceus is a symbol of medicine and healing. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES · USA" is arranged in a circular pattern around the caduceus symbol.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Cynthia C. Knapp Director Lab Services TREK Diagnostic Systems, Inc. 982 Keynote Circle, Suite 6 Cleveland, OH 44131
OCT 26 2006
Re: K062783 Trade/Device Name: Sensititre® Haemophilus influenza/Streptococcus pneumoniae (HP) MIC susceptibility plates, for Gemifloxacin (0.03-0.5 ug/ml), Linezolid (1 - 8 ug/ml), Levefloxacin (0.5 - 16 ug/ml), Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System Regulatory Class: Class II Product Code: JWY, LRG Dated: September 14, 2006 Received: September 18, 2006
Dear Ms. Knapp:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirernents, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820),
{1}------------------------------------------------
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or guestions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sally antonm
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known): 62793
Device Name: Sensititre® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility Plates. Gemifloxacin (0.03-0.5ug/ml), Linezolid (1-8 ug/ml), Levofloxacin (0.5-16 ug/ml)
Indications For Use: The Sensititre® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Haemophilus influenzae; Streptococcus pneumoniae and Streptococcus species.
This 510(k) is for the addition of Streptococcus spps. to Gemifloxacin (0.03 -0.5 ug/mL), Linezolid (0.5-4 ug/mL), Levolloxacin (0.5-16 ug/mL) for use with the Sensitite® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility Plates.
The approved primary "indications for use" and clinical significance of Gemilloxacin is for: Streptococcus pneumoniae
The following in vitro data are available but their clinical significance is unknown: Streptococcus pyogenes
The approved primary "indications for use" and clinical significance of Linezolid is for Streptococcus pneumoniae, (including multi-drug resistant strains) Streptococcus agalactiae Streptococcus pvogenes
The following in vitro data are available but their clinical significance is unknown: Viridans group streptococci
The approved primary "indications for use" and clinical significance of Levofloxacin is for: Streptococcus pneumoniae (including multi-drug resistant strains) Streptococcus pyogenes
The following in vitro data are available but their clinical significance is unknown:
Viridans group streptococci Streptococcus agalactiae Streptococcus (Group C/F) Streptococcus (Group G) Streptococcus milleri
Prescription Use
AND/OR
Over-The-Counter Use
(Part 21 CFR 801 Subpart D)
(21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) | |||||||
|---|---|---|---|---|---|---|---|
| -- | ------------------------------------------------------------------- | -- | -- | -- | -- | -- | -- |
Freddie M. Focke
Division Sign-Off
;vice
Evaluation and Safe
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).